Profile: Genentech, Inc delivers medicines to patients with serious or life-threatening medical conditions. Our avastin is a therapy designed to inhibit angiogenesis, the process by which new blood vessels develop & carry vital nutrients to a tumor. Our rituxan is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive and B-cell non-hodgkin's lymphoma (NHL). Our Herceptin® is an anti-HER2 antibody used for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer. It is also indicated in combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer and as a single agent for the treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.

The company has revenues of USD 100-500 Million, has ~1800 employees. NYSE:GNE (SEC Filings)